PUBLISHER: The Business Research Company | PRODUCT CODE: 1811002
PUBLISHER: The Business Research Company | PRODUCT CODE: 1811002
A pharmaceutical contract development and manufacturing organization (CDMO) for formulations is a company that offers outsourced services to support the development and production of drug formulations on behalf of pharmaceutical companies. These services typically include formulation development, analytical testing, production of clinical trial materials, and large-scale commercial manufacturing.
The primary types of dosage forms provided by pharmaceutical CDMOs for formulations include oral solids, oral liquids, injectables, topicals, inhalation products, transdermals and patches, among others. Oral solid dosage forms are medications administered orally and designed to deliver the active drug through the digestive system. These dosage forms are applied across various therapeutic areas such as oncology, cardiology, central nervous system disorders, gastroenterology, infectious diseases, and endocrinology. The services are utilized by a range of end users, including pharmaceutical companies, biopharmaceutical firms, and other related organizations.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The pharmaceutical contract development and manufacturing organizations (CDMO) for formulations market research report is one of a series of new reports from The Business Research Company that provides pharmaceutical contract development and manufacturing organizations (CDMO) for formulations market statistics, including the pharmaceutical contract development and manufacturing organizations (CDMO) for formulations industry global market size, regional shares, competitors with the pharmaceutical contract development and manufacturing organizations (CDMO) for formulations market share, detailed pharmaceutical contract development and manufacturing organizations (CDMO) for formulations market segments, market trends, opportunities, and any further data you may need to thrive in the pharmaceutical contract development and manufacturing organizations (CDMO) for formulations industry. This pharmaceutical contract development and manufacturing organizations (CDMO) for formulations market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The pharmaceutical contract development and manufacturing organization (CDMO) for formulations market size has grown rapidly in recent years. It will grow from $49.32 billion in 2024 to $54.73 billion in 2025 at a compound annual growth rate (CAGR) of 11.0%. The growth during the historic period can be attributed to the rise in pharmaceutical outsourcing, increasing complexity of drug formulations, cost-reduction strategies adopted by pharmaceutical companies, growing demand for generics and biosimilars, and the expansion of small and mid-sized pharmaceutical firms.
The pharmaceutical contract development and manufacturing organization (CDMO) for formulations market size is expected to see rapid growth in the next few years. It will grow to $82.15 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to the surge in biologics and advanced therapies, the expansion of personalized medicine, increasing emphasis on continuous manufacturing, regulatory encouragement for outsourcing, and the rising adoption of digitalization and automation in pharmaceutical production. Key trends anticipated during this period include the advancement of continuous manufacturing technologies, integration of AI and machine learning in drug development processes, expansion of high-potency API (HPAPI) handling capabilities, increased adoption of biologics and complex injectable formulations, and a growing focus on sustainable and environmentally friendly manufacturing practices.
The increasing activities in drug development and manufacturing are expected to drive the growth of the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market. Drug development and manufacturing refer to the efforts by pharmaceutical and biopharmaceutical companies to research, develop, and produce new therapeutic drugs. These activities are rising due to the growing global demand for novel and effective treatments, which encourages companies to broaden their development pipelines and accelerate production timelines. CDMOs support this process by formulating and optimizing dosage forms, conducting stability testing, ensuring regulatory compliance, and managing scale-up and production. This enables quicker and more cost-effective product launches. For example, in June 2023, the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based pharmaceutical industry trade group, reported that pharmaceutical production in Europe reached $422.8 billion (€390 billion) in 2023, up from $393.9 billion (€363.3 billion) in 2022. Therefore, the expansion of drug development and manufacturing is contributing to the growth of the CDMO market for formulations.
Leading companies in the pharmaceutical CDMO for formulations market are focusing on the development of advanced biologic formulation platforms to improve drug stability and speed up delivery timelines for complex biologic therapies. These biologic formulation platforms are specialized systems that optimize various formulation parameters-such as pH levels, excipients, and delivery mechanisms-to enhance the stability, safety, and bioavailability of biologic drugs throughout their lifecycle. For example, in June 2025, WuXi Biologics, a China-based contract research, development, and manufacturing company, introduced WuXiHigh 2.0, a next-generation high-concentration formulation platform. This platform allows biologic formulations with protein concentrations up to 230 mg/mL, exceeding the FDA-approved limit of 200 mg/mL. It also reduces viscosity by up to 90% through proprietary excipient blends and high-throughput screening. WuXiHigh 2.0 addresses key challenges in high-concentration biologics-such as aggregation and viscosity-while improving injection efficiency, patient compliance, and manufacturing performance throughout the clinical and commercial stages.
In February 2025, Jabil Inc., a US-based provider of engineering, manufacturing, and supply chain services, acquired Pharmaceutics International Inc. (Pii) for an undisclosed amount. This acquisition is intended to enhance Jabil's capabilities in pharmaceutical manufacturing and development by leveraging Pii's expertise in aseptic filling, lyophilization, and oral solid dose production. It strengthens Jabil's position in parenteral drug delivery and broadens its comprehensive support across both clinical and commercial manufacturing. Pharmaceutics International Inc. (Pii) is a US-based CDMO that offers formulation development services for a variety of drug forms, ranging from injectable to oral products.
Major players in the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market are Thermo Fisher Scientific Inc., Lonza Group, Catalent Inc., WuXi Biologics, Samsung Biologics, Recipharm AB, Siegfried Holding AG, Evonik Industries AG, Almac Group, Aenova Group, Piramal Pharma Limited, Cambrex, Jubilant Pharmova Limited, CordenPharma, Altasciences, Hovione, Aurigene Pharmaceutical Services Ltd., DPT Laboratories Ltd., CARBOGEN AMCIS, Biopharma Group, LGM Pharma, and Aarti Pharmalabs Limited.
Asia-Pacific was the largest region in the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in pharmaceutical contract development and manufacturing organization (CDMO) for formulations report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The pharmaceutical contract development and manufacturing organization (CDMO) for formulations market consists of revenues earned by entities by providing services such as analytical and stability testing, formulation development, process development and scale-up, regulatory support and documentation, and commercial-scale manufacturing and packaging. The market value includes the value of related goods sold by the service provider or included within the service offering. The pharmaceutical contract development and manufacturing organization (CDMO) for formulations market also includes sales of suppositories, ophthalmic preparations, buccal and sublingual tablets, liposomal formulations, and microneedle patches. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on pharmaceutical contract development and manufacturing organization (cdmo) for formulations market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for pharmaceutical contract development and manufacturing organization (cdmo) for formulations ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pharmaceutical contract development and manufacturing organization (cdmo) for formulations market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.